Selective inhibitors of the FK506-binding protein 51 by induced fit

Nature Chemical Biology

Volumn 11, Issue 1, 2015, Pages 33-37

  Gaali, Steffen ^a   Kirschner, Alexander ^a   Cuboni, Serena ^a   Hartmann, Jakob ^a   Kozany, Christian ^a,g   Balsevich, Georgia ^a   Namendorf, Christian ^a   Fernandez Vizarra, Paula ^a   Sippel, Claudia ^a   Zannas, Anthony S ^a,b   Draenert, Rika ^c   Binder, Elisabeth B ^a,d   Almeida, Osborne F X ^a   Rühter, Gerd ^e   Uhr, Manfred ^a   Schmidt, Mathias V ^a   Touma, Chadi ^a   Bracher, Andreas ^f   Hausch, Felix ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Lead Discovery Center GmbH   (Germany)

^f MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^g Sequiserve   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTASCOMYCIN B; ANTIDEPRESSANT AGENT; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 51; FK 506 BINDING PROTEIN 52; IFIT 1; IFIT 2; IFIT 3; IFIT 4; ISOMERASE INHIBITOR; RAPAMYCIN; SAFIT 1; SAFIT 2; TACROLIMUS; UNCLASSIFIED DRUG; TACROLIMUS BINDING PROTEIN 4; TACROLIMUS BINDING PROTEIN 5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING SITE; CELL ELONGATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; COPING BEHAVIOR; CRYSTAL STRUCTURE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; FLUORESCENCE POLARIZATION; IMMUNE RESPONSE; LIGAND BINDING; MALE; MOUSE; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; ADAPTIVE BEHAVIOR; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; HUMAN; MUTATION; NEURITE; PROTEIN CONFORMATION;

ADAPTATION, PSYCHOLOGICAL; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BINDING SITES; CELLS, CULTURED; DRUG DISCOVERY; HUMANS; MALE; MICE; MICE, INBRED C57BL; MUTATION; NEURITES; PROTEIN CONFORMATION; TACROLIMUS BINDING PROTEINS;

EID: 84914165739     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1699     Document Type: Article

References (57)

1. Cioffi, D.L., Hubler, T.R. & Scammell, J.G. Organization and function of the FKBP52 and FKBP51 genes. Curr. Opin. Pharmacol. 11, 308-313 (2011).
2. Sanchez, E.R. Chaperoning steroidal physiology: lessons from mouse genetic models of Hsp90 and its cochaperones. Biochim. Biophys. Acta 1823, 722-729 (2012).
3. Schmidt, M.V., Paez-Pereda, M., Holsboer, F. & Hausch, F. The prospect of FKBP51 as a drug target. ChemMedChem 7, 1351-1359 (2012).
4. Storer, C.L., Dickey, C.A., Galigniana, M.D., Rein, T. & Cox, M.B. FKBP51 and FKBP52 in signaling and disease. Trends Endocrinol. Metab. 22, 481-490 (2011).
5. Gaali, S., Gopalakrishnan, R., Wang, Y., Kozany, C. & Hausch, F. The chemical biology of immunophilin ligands. Curr. Med. Chem. 18, 5355-5379 (2011).
6. Cheung-Flynn, J. et al. Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol. Endocrinol. 19, 1654-1666 (2005).
7. Tranguch, S. et al. Cochaperone immunophilin FKBP52 is critical to uterine receptivity for embryo implantation. Proc. Natl. Acad. Sci. USA 102, 14326-14331 (2005).
8. Yang, Z. et al. FK506-binding protein 52 is essential to uterine reproductive physiology controlled by the progesterone receptor A isoform. Mol. Endocrinol. 20, 2682-2694 (2006).
9. Yong, W. et al. Essential role for co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology. J. Biol. Chem. 282, 5026-5036 (2007).
10. Attwood, B.K. et al. Neuropsin cleaves EphB2 in the amygdala to control anxiety. Nature 473, 372-375 (2011).
11. Hartmann, J. et al. The involvement of FK506-binding protein 51 (FKBP5) in the behavioral and neuroendocrine effects of chronic social defeat stress. Neuropharmacology 62, 332-339 (2012).
12. O'Leary, J.C. III et al. A new anti-depressive strategy for the elderly: ablation of FKBP5/FKBP51. PLoS ONE 6, e24840 (2011).
13. Touma, C. et al. FK506 binding protein 5 shapes stress responsiveness: modulation of neuroendocrine reactivity and coping behavior. Biol. Psychiatry 70, 928-936 (2011).
14. Albu, S. et al. Deficiency of FK506-binding protein (FKBP) 51 alters sleep architecture and recovery sleep responses to stress in mice. J. Sleep Res. 23, 176-185 (2014).
15. Zannas, A.S. & Binder, E.B. Gene-environment interactions at the FKBP5 locus: sensitive periods, mechanisms and pleiotropism. Genes Brain Behav. 13, 25-37 (2014).
16. Zou, Y.-F. et al. Meta-Analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neurosci. Lett. 484, 56-61 (2010).
17. Blackburn, E.A. & Walkinshaw, M.D. Targeting FKBP isoforms with small-molecule ligands. Curr. Opin. Pharmacol. 11, 365-371 (2011).
18. Fabian, A.-K. et al. InterAKTions with FKBPs-mutational and Pharmacological Exploration. PLoS ONE 8, e57508 (2013).
19. Hausch, F., Kozany, C., Theodoropoulou, M. & Fabian, A.-K. FKBPs and the Akt/mTOR pathway. Cell Cycle 12, 2366-2370 (2013).
20. Bracher, A. et al. Crystal structures of the free and ligand-bound FK1-FK2 domain segment of FKBP52 reveal a flexible inter-domain hinge. J. Mol. Biol. 425, 4134-4144 (2013).
21. Bracher, A., Kozany, C., Thost, A.K. & Hausch, F. Structural characterization of the PPIase domain of FKBP51, a cochaperone of human Hsp90. Acta Crystallogr. D Biol. Crystallogr. 67, 549-559 (2011).
22. März, A.M., Fabian, A.-K., Kozany, C., Bracher, A. & Hausch, F. Large FK506-binding proteins shape the pharmacology of rapamycin. Mol. Cell. Biol. 33, 1357-1367 (2013).
23. Clackson, T. et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc. Natl. Acad. Sci. USA 95, 10437-10442 (1998).
24. Banaszynski, L.A., Chen, L.-C., Maynard-Smith, L.A., Ooi, A.G.L. & Wandless, T.J.A. Rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 126, 995-1004 (2006).
25. Quintá, H.R., Maschi, D., Gomez-Sanchez, C., Piwien-Pilipuk, G. & Galigniana, M.D. Subcellular rearrangement of hsp90-binding immunophilins accompanies neuronal differentiation and neurite outgrowth. J. Neurochem. 115, 716-734 (2010).
26. Evans, D.A., Ennis, M.D., Le, T., Mandel, N. & Mandel, G. Asymmetric acylation reactions of chiral imide enolates. The first direct approach to the construction of chiral β-dicarbonyl synthons. J. Am. Chem. Soc. 106, 1154-1156 (1984).
27. Myers, A.G. et al. Pseudoephedrine as a practical chiral auxiliary for the synthesis of highly enantiomerically enriched carboxylic acids, alcohols, aldehydes, and ketones. J. Am. Chem. Soc. 119, 6496-6511 (1997).
28. Gopalakrishnan, R. et al. Evaluation of synthetic FK506 analogues as ligands for the FK506-binding proteins 51 and 52 J. Med. Chem. 55, 4114-4122 (2012).
29. Gopalakrishnan, R. et al. Exploration of pipecolate sulfonamides as binders of the FK506-binding proteins 51 and52 J. Med. Chem. 55, 4123-4131 (2012).
30. Wang, Y. et al. Increasing the efficiency of ligands for FK506-binding protein 51 by conformational control. J. Med. Chem. 56, 3922-3935 (2013).
31. Weiwad, M. et al. Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins. Biochemistry 45, 15776-15784 (2006).
32. Price, R.D. et al. FK1706, a novel non-immunosuppressive immunophilin: neurotrophic activity and mechanism of action. Eur. J. Pharmacol. 509, 11-19 (2005).
33. Revill, W.P. et al. Genetically engineered analogs of ascomycin for nerve regeneration. J. Pharmacol. Exp. Ther. 302, 1278-1285 (2002).
34. Babine, R.E., Villafranca, J.E. & Gold, B.G. FKBP immunophilin patents for neurological disorders. Expert. Opin. Ther. Patents 15, 555-573 (2005).
35. Gerard, M., Deleersnijder, A., Demeulemeester, J., Debyser, Z. & Baekelandt, V. Unraveling the role of peptidyl-prolyl isomerases in neurodegeneration. Mol. Neurobiol. 44, 13-27 (2011).
36. Gold, B.G., Densmore, V., Shou, W., Matzuk, M.M. & Gordon, H.S. Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. J. Pharmacol. Exp. Ther. 289, 1202-1210 (1999).
37. Sugimoto, Y. et al. Differences between mice strains in response to paroxetine in the forced swimming test: involvement of serotonergic or noradrenergic systems. Eur. J. Pharmacol. 672, 121-125 (2011).
38. Touma, C. Stress and affective disorders: animal models elucidating the molecular basis of neuroendocrine-behavior interactions. Pharmacopsychiatry 44 (suppl. 1), S15-S26 (2011).
39. Hartmann, J. et al. Fkbp52 heterozygosity alters behavioral, endocrine and neurogenetic parameters under basal and chronic stress conditions in mice. Psychoneuroendocrinology 37, 2009-2021 (2012).
40. Raison, C.L. & Miller, A.H. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am. J. Psychiatry 160, 1554-1565 (2003).
41. Ising, M. et al. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression-A potential biomarker? Biol. Psychiatry 62, 47-54 (2007).
42. Klengel, T. et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat. Neurosci. 16, 33-41 (2013).
43. Kozany, C., März, A., Kress, C. & Hausch, F. Fluorescent probes to characterise FK506-binding proteins. ChemBioChem 10, 1402-1410 (2009).
44. Brittain, D.E. et al. Total synthesis of antascomicin B. Angew. Chem. Int. Edn. Engl. 44, 2732-2737 (2005).
45. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
46. Evans, P. Scala. Joint CCP4 and ESF-EACBM Newsletter 33, 22-24 (1997).
47. French, G.S. & Wilson, K.S. On the treatment of negative intensity observations. Acta Crystallogr. A 34, 517-525 (1978).
48. Collaborative Computational Project N. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr 50, 760-763 (1994).
49. Vagin, A.A. & Isupov, M.N. Spherically averaged phased translation function and its application to the search for molecules and fragments in electron-density maps. Acta Crystallogr. D Biol. Crystallogr. 57, 1451-1456 (2001).
50. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
51. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
52. Schüttelkopf, A.W. & van Aalten, D.M.F. PRODRG-A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60, 1355-1363 (2004).
53. Delano, W.L. The Pymol Molecular Graphics System (DeLano Scientific, 2002).
54. Draenert, R. et al. Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J. Immunol. Methods 275, 19-29 (2003).
55. Beurel, E., Harrington, L.E. & Jope, R.S. Inflammatory T helper 17 cells promote depression-like behavior in mice. Biol. Psychiatr. 73, 622-630 (2013).
56. Zhang, Y., Huo, M., Zhou, J. & Xie, S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput. Methods Programs Biomed. 99, 306-314 (2010).
57. Touma, C. et al. Mice selected for high versus low stress reactivity: a new animal model for affective disorders. Psychoneuroendocrinology 33, 839-862 (2008).